– Hippocampal NMDA receptors play a central role in emotionality and cognition, impacting fear, anxiety, and depression. – NMDA receptor antagonists affect anxiety and depression by targeting NMDA receptors in the hippocampus, especially the ventral part. – The ventral hippocampus is crucial for anxiolytic effects and is linked to emotional processing areas like the prefrontal cortex and amygdala. – Studies show that hippocampal lesions, particularly in the ventral hippocampus, reduce anxiety. – The hippocampus, traditionally known for memory, is implicated in anxiety and depression, with the ventral region being particularly relevant. – Genetically modified mice lacking specific NMDA receptor subunits in the hippocampus exhibit reduced anxiety, supporting the role of hippocampal NMDA receptors in anxiety regulation. – Cellular mechanisms underlying anxiety and depression, emphasizing the importance of further studies with genetically modified mice to uncover these mechanisms. – Interactions between NMDA receptors and other neurotransmitter systems, such as glycine-B receptors, serotonin receptors, and GABA(A) receptors, also play a role in modulating anxiety and depression. – Various behavioral tests, including the elevated plus maze and conditioned fear conditioning paradigms, have been used to assess the effects of NMDA receptor modulation on anxiety and depression-related behaviors.
Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.
Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.
